Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTEM: Repotrectinib + Osimertinib in EGFR-mutant NSCLC
NCT04772235Phase 1Recruiting
- Sponsor
- Instituto Oncológico Dr. Rosell
- Start
- Feb 2022
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of repotrectinib in non-small cell lung cancer (NSCLC), sponsored by Instituto Oncológico Dr. Rosell. Primary endpoints: Adverse Events at 48 months and Incidence of Dose Limiting Toxicities at 21 days. Started Feb 2022; status: recruiting.
02
Drugs
repotrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04772235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772235.